Thin basement membrane disease (TBMD, also known as
benign familial hematuria and
thin basement membrane nephropathy) is, along with
IgA nephropathy, the most common cause of asymptomatic
hematuria. The only abnormal finding in this disease is a thinning of the
basement membrane of the
glomeruli in the kidneys. Its importance lies in the fact that it has a benign
prognosis, with patients maintaining a normal
kidney function throughout their lives.
Signs and symptoms
Most patients with thin basement membrane disease are incidentally discovered to have
microscopic hematuria on
urinalysis. The
blood pressure,
kidney function and the urinary protein excretion are usually normal. Mild
proteinuria (less than 1.5 g/day) and
hypertension are seen in a small minority of patients. Frank
hematuria and loin pain should prompt a search for another cause, such as
kidney stones or
loin pain-hematuria syndrome. Also, there are no systemic manifestations, so presence of
hearing impairment or
visual impairment should prompt a search for
hereditary nephritis such as
Alport syndrome.
Diagnosis
Thin basement membrane disease has to be differentiated from the other two common causes of isolated
glomerular hematuria,
IgA nephropathy and
Alport syndrome. The history and presentation are helpful in this regard:
A kidney biopsy is the only way to diagnose thin basement membrane disease. It reveals thinning of the glomerular basement membrane from the normal 300 to 400 nanometers (nm) to 150 to 250 nm. However, a biopsy is rarely done in cases where the patient has isolated microscopic hematuria, normal kidney function and no proteinuria. The prognosis is excellent in this setting unless the clinical manifestations progress, as occurs in all males and some females with Alport syndrome and many patients with IgA nephropathy.
Genetics
The molecular basis for thin basement membrane disease has yet to be elucidated fully; however, defects in the gene encoding the a4 chain of type IV collagen have been reported in some families.
Some individuals with TBMD are thought to be carries for genes that cause Alport syndrome.
Treatment
Most patients with thin basement membrane disease need just reassurance.
Angiotensin converting enzyme inhibitors have been suggested to reduce the episodes of
hematuria, though controlled studies are lacking. Treating co-existing
hypercalciuria and
hyperuricosuria will also be helpful in reducing
hematuria.
The molecular basis for thin basement membrane disease has yet to be elucidated fully; however, defects in the gene encoding the a4 chain of type IV collagen have been reported in some families.
Prognosis
Overall, most people with thin basement membrane disease have an excellent
prognosis. Some reports, however, suggest that a minority might develop
hypertension. The high incidence of thin basement disease also means that it may be co-existing with other kidney diseases, such as
diabetic nephropathy, which may have a not-so-benign prognosis.
References
- Buzza M, Wang Y, Dagher H, Babon J, Cotton R, Powell H, Dowling J, Savige J. COL4A4 mutation in thin basement membrane disease previously described in Alport syndrome. Kidney International (2001) 60, 480–483. PMID 11473630
- Nieuwhof, CM, de Heer, F, de Leeuw, P, van Breda Vriesman, PJ. Thin GBM nephropathy. Premature glomerular obsolescence is associated with hypertension and late onset renal failure. Kidney Int 1997;51:1596. PMID 9150478